Harmony Biosciences Holdings, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Harmony Biosciences Holdings, Inc. - overview
Established
2017
Location
Plymouth Meeting, PA, US
Primary Industry
Pharmaceuticals
About
Based in Pennsylvania, US, and founded in 2017 by Paragon Biosciences LLC, Harmony Biosciences Holdings, Inc. operates as a pharmaceutical company that develops and commercializes therapies for individuals with rare neurological disorders who have unmet medical needs. The firm is trading under the NYSE under the ticker symbol HRMY. The company received investment from Fidelity Investments, HBM Partners, Nan Fung Life Sciences, Novo Holdings A/S, Valor Equity Partners, VenBio Partners, and Vivo Capital in 2017, and in April 2025, Adage Capital Partners GP L.
L. C. , JPMorgan Chase & Co. , Swiss National Bank, Teacher Retirement System of Texas, Vanguard Group Inc.
, Barclays PLC acquired Harmony Biosciences Holdings, Inc, as part of a PIPE deal. Financial terms of the transaction were not disclosed. The firm focuses on the research, treatment, and drug development for neurologic disorders of sleep-wake state instability that impacts approximately 165,000 Americans. The company generated USD 159.
74 in revenue and USD 24. 15 in EBITDA in 2020. Following its strategic financing with Blackstone, Harmony Biosciences Holdings, Inc. plans to use the capital to strengthen its balance sheet, reduce its annual interest expense, further grow its business by accessing capital to expand its portfolio of assets.
Current Investors
Blackstone Group, Teacher Retirement System of Texas, JP Morgan Chase & Co (Formerly Bear Stearns Private Fund Group)
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.harmonybiosciences.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Harmony Biosciences Holdings, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | Harmony Biosciences Holdings, Inc. | - | ||||||||
| Add-on, Trade Sale | Completed | Zynerba Pharmaceuticals, Inc | - | ||||||||
| PIPE | Completed | Harmony Biosciences Holdings, Inc. | - | ||||||||
| Private Debt | Completed | Harmony Biosciences Holdings, Inc. | - |
Displaying 1 - 4 of 4
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.